MA34556B1 - Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger - Google Patents

Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Info

Publication number
MA34556B1
MA34556B1 MA35785A MA35785A MA34556B1 MA 34556 B1 MA34556 B1 MA 34556B1 MA 35785 A MA35785 A MA 35785A MA 35785 A MA35785 A MA 35785A MA 34556 B1 MA34556 B1 MA 34556B1
Authority
MA
Morocco
Prior art keywords
fusioned
triazoles
prophylaxis
treatment
cognitive disorders
Prior art date
Application number
MA35785A
Other languages
English (en)
French (fr)
Inventor
Tatsuki Koike
Minoru Nakamura
Yoshihide Tomata
Takafumi Takai
Yasutaka Hoashi
Yuichi Kajita
Tetsuya Tsukamoto
Makoto Kamata
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34556(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34556B1 publication Critical patent/MA34556B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA35785A 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger MA34556B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
MA34556B1 true MA34556B1 (fr) 2013-09-02

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35785A MA34556B1 (fr) 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Country Status (22)

Country Link
US (3) US8822699B2 (cg-RX-API-DMAC7.html)
EP (1) EP2611805A1 (cg-RX-API-DMAC7.html)
JP (1) JP5871909B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130139895A (cg-RX-API-DMAC7.html)
CN (1) CN103249733A (cg-RX-API-DMAC7.html)
AR (1) AR082865A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011296887A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013004746A2 (cg-RX-API-DMAC7.html)
CA (1) CA2809779A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000575A1 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000051A (cg-RX-API-DMAC7.html)
EA (1) EA201390333A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012535A (cg-RX-API-DMAC7.html)
MA (1) MA34556B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013002511A (cg-RX-API-DMAC7.html)
PE (1) PE20131305A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500403A1 (cg-RX-API-DMAC7.html)
SG (1) SG187917A1 (cg-RX-API-DMAC7.html)
TW (1) TW201213327A (cg-RX-API-DMAC7.html)
UY (1) UY33586A (cg-RX-API-DMAC7.html)
WO (1) WO2012029991A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301929B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482276A (zh) * 2009-07-13 2012-05-30 武田药品工业株式会社 杂环化合物及其用途
EA201390333A1 (ru) * 2010-09-02 2013-08-30 Такеда Фармасьютикал Компани Лимитед Конденсированные триазолы для лечения или профилактики умеренного когнитивного нарушения
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
JP7000160B2 (ja) * 2015-05-12 2022-01-19 エフ エム シー コーポレーション 除草剤としてのアリール置換二環式化合物
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US7402592B2 (en) * 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
US20090221611A1 (en) 2006-01-11 2009-09-03 Devita Robert J Fused Triazole Tachykinin Receptor Antagonists
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
HRP20120174T1 (hr) 2006-03-09 2012-03-31 Eisai R&D Management Co. Derivat policikličnog cinamida
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
TW200835502A (en) 2006-12-26 2008-09-01 Daiichi Sankyo Co Ltd Thiazepine derivatives
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
CA2707712A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
RU2515976C2 (ru) * 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
CN102482276A (zh) * 2009-07-13 2012-05-30 武田药品工业株式会社 杂环化合物及其用途
AP2011006034A0 (en) 2009-07-15 2011-12-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators.
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
EA201390333A1 (ru) * 2010-09-02 2013-08-30 Такеда Фармасьютикал Компани Лимитед Конденсированные триазолы для лечения или профилактики умеренного когнитивного нарушения

Also Published As

Publication number Publication date
JP2013536798A (ja) 2013-09-26
WO2012029991A1 (en) 2012-03-08
JP5871909B2 (ja) 2016-03-01
CA2809779A1 (en) 2012-03-08
ECSP13012535A (es) 2013-06-28
PH12013500403A1 (en) 2013-03-25
ZA201301929B (en) 2013-11-27
DOP2013000051A (es) 2013-04-30
EP2611805A1 (en) 2013-07-10
TW201213327A (en) 2012-04-01
US20140350260A1 (en) 2014-11-27
SG187917A1 (en) 2013-04-30
PE20131305A1 (es) 2013-10-31
CN103249733A (zh) 2013-08-14
UY33586A (es) 2012-03-30
AR082865A1 (es) 2013-01-16
US8822699B2 (en) 2014-09-02
KR20130139895A (ko) 2013-12-23
EA201390333A1 (ru) 2013-08-30
AU2011296887A1 (en) 2013-04-11
US8901309B2 (en) 2014-12-02
US20130178497A1 (en) 2013-07-11
US20120059030A1 (en) 2012-03-08
MX2013002511A (es) 2013-07-29
CL2013000575A1 (es) 2013-08-23
BR112013004746A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
MA34556B1 (fr) Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA34713B1 (fr) Compose bicyclique
EA201791070A1 (ru) Способы получения ингибиторов ask1
MA41553B1 (fr) Sulfonylurées, composés apparentés, et leur utilisation
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA44948A1 (fr) Inhibiteurs de bace 1
EA201692048A1 (ru) Дигидротиазин и дигидрооксазин производные, обладающие ингибирующей bace1 активностью
MA39246A1 (fr) Composé hétérocyclique fusionné
PE20180233A1 (es) Nuevos compuestos biciclicos como inhibidores duales de atx / ca
GEP20166554B (en) Nitrogenated heterocyclic compound
EA200500322A1 (ru) Соединения дигидропиразолопиридина
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4